2BARBUTO J A, ENSINA L F, NEVES A R, et al. Dendritic cell-tumor cell hybrid vaccination for meta static cancer[J]. Canc-er Immunol Immunother, 2004, 53:1111-1118.
3WILSON N, MIKOL C, DONALDSON A, et al. Den dritlc cell im-munotherapy for advanced metastatic melanoma : intermreport [J]. J Immunotherapy, 2005, 28(6) :661.
4YU JOHN S M D,LIU GENTAO PHD, NG HIUSHAN M S,et al. Aphase I trial of intracranial dendritic cell immunotherapyfor patients with malignant glioma : 894[J]. Neurosurgery, 2006,59 : 485 - 485.
5SAUMA D, MICHEA P, LENNON-DUMENIL A M, et al. Interleu-kin-4 selectively inhibits interleukin- 2 secretion by lipopo-lysaccaride-activated dendritic cells[J]. Scandinavian Jurn Immunol, 2004,59 : 183 - 189.
6YOSHIURA K, NAKAOA T, NISHISHITA T, et al. Carbonic an-hydase Ⅱ is a tumor vessel endothelium associated anti-gen targeted by dendritic cell therapy[J]. Clin Cancer Res,2005,11:8201-8207.
7MAYORDOMO J L, ANDRES R, ISLAM D, et al Results of a pilottrial of immunotherapy with dendritic cells pulsed withautologous tumor lysates in patients with advanced canc-er[J]. Tumori, 2007, 93:26.
8ADAM C, MYSLIWIETZ J, MOCIKAT R. Specific targeting of whole lymphoma cells to dendritic cells ex vivo provides apotent antitumor vaccine[J]. J Transl Med,2007,5:16-16.
9LISAH B, ANTONI R, VIVAN B D, et al. Determinant spreading associated with clinical response in dendritic cell based immunotherapy for malignant melanoma[J]. Clin Cancer Res, 2003,9 : 998 - 1008.
1Barbuto JA, Ensina LF, Neves AR et al. Dendritic celltumor cell hybrid vaccination for metastatic cancer. Cancer Immunol Immunother, 2004,53 (12) : 1111
2Wilson N, Mikol C,Donaldson A et al. Dendritic cell immunotherapy for advanced metastatic melanoma, interim report. Journal of Immunotherapy, 20(15,28(6) : 661
3Yu John SMD,Liu Gentao PhD,Ng Hiushan MS et al. A phase I trial of intracranial dendritic cell irnmunotherapy for patients with malignant glioma. 894. Neurosurgery, 2006,59(2):485
4Sauma D, Michea P, Lennon-Dumenil AM et al. Interleukin-4 selectively inhibits interleukin-2 secretion by lipopolysaccaride-activated dendritic cells, scandinavian journal of immunology,2004,59(2) : 183
5Kalady MF,Onaitis MW, Emani Set al. Sequential delivery of maturation stimuli increases human dendritic cell IL-12 production and enhances tumor antigen-specific immunogenicity, Surg Res, 2004,116 (1) : 24
6Gao N, Flynn DC, Zhang Z et al. G1 cell cycle progression and the expression of G1 cyclins are regulated byPI3K/ AKT/mTOR/pTOS6K1 signaling in human ovarian cancer cells. Am J Physiol Cell Physiol,2004,287(2) : 281
7Xu G, Zhang WH, Bertram Pet al. Pharmacogenornic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors. Int J Oncol,2004,24(9):893
8Yoshiura K, Nakaoka T, Nishishita T et al. Carbonic anhydrase Ⅱ is a tumor vessel endothelium-associated antigen targeted by dendritic cell therapy. Clin Cancer Res, 2005,11 (22) :8201
9Mayordomo JI,Andres R,Isla MD et al. Results of a pilot trial of immunotherapy with dendritic cells pulsed with autologous tumor lysates in patients with advanced cancer. Tumori,2007,93(1) :26
10Adam C, Mysliwietz J, Mocikat R. Specific targeting of whole lymphoma cells to dendritic cells ex vivo provides a potent antitumor vaccine. J Transl Med, 2007,5 ( 1 ): 16
